PE20070457A1 - Composicion que comprende un inhibidor del receptor del factor de crecimiento endotelial vascular - Google Patents

Composicion que comprende un inhibidor del receptor del factor de crecimiento endotelial vascular

Info

Publication number
PE20070457A1
PE20070457A1 PE2006001109A PE2006001109A PE20070457A1 PE 20070457 A1 PE20070457 A1 PE 20070457A1 PE 2006001109 A PE2006001109 A PE 2006001109A PE 2006001109 A PE2006001109 A PE 2006001109A PE 20070457 A1 PE20070457 A1 PE 20070457A1
Authority
PE
Peru
Prior art keywords
receptor
growth factor
substituted
nitro
halogen
Prior art date
Application number
PE2006001109A
Other languages
English (en)
Inventor
Andreas Billich
Anton Stutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0518672A external-priority patent/GB0518672D0/en
Priority claimed from GB0518671A external-priority patent/GB0518671D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070457A1 publication Critical patent/PE20070457A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) COMPUESTOS INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR DE FORMULA (I) DONDE R1 ES H, HALOGENO, (C0-C7)-R3, ENTRE OTROS, DONDE R3 ES H O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON AMINO, OH, CN, NITRO, ENTRE OTROS; R2 ES CICLOALQUILO(C3-C8) SUSTITUIDO CON CN, NITRO, CARBOXILO, ENTRE OTROS SUSTITUYENTES, ARILO SUSTITUIDO CON CN, UREIDO, HALOGENO, ENTRE OTROS SUSTITUYENTES, O HETEROCICLILO SUSTITUIDO CON CN, NITRO, GUANIDINO, ENTR E OTROS; A, B Y X SON =C(R7)- O N; E, G Y T SON =C(R8)- O N, DONDE R7 Y R8 SON CADA UNO H, HALOGENO O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON AMINO, OH, CN, NITRO, ENTRE OTROS; Y ES O, S, S(O), S(O)2, ENTRE OTROS; Z ES CH, N O C; Q ES ALQUILENO(C1-C4) O ALQUENILENO(C2-C4); ---- ES UN ENLACE SIMPLE O DOBLE; W ESTA AUSENTE, ES ALQUILENO(C1-C3), ENTRE OTROS; SIENDO PREFERIDO UN COMPUESTO DE FORMULA (i); Y B) UN POTENCIADOR DE ABSORCION TAL COMO ACIDOS GRASOS INSATURADOS, ESTERES DE ACIDOS GRASOS INSATURADOS, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE PSORIASIS, DERMATITIS ATOPICA, ACNE
PE2006001109A 2005-09-13 2006-09-12 Composicion que comprende un inhibidor del receptor del factor de crecimiento endotelial vascular PE20070457A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0518672A GB0518672D0 (en) 2005-09-13 2005-09-13 Organic compounds
GB0518671A GB0518671D0 (en) 2005-09-13 2005-09-13 Organic compounds

Publications (1)

Publication Number Publication Date
PE20070457A1 true PE20070457A1 (es) 2007-06-06

Family

ID=37663150

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001109A PE20070457A1 (es) 2005-09-13 2006-09-12 Composicion que comprende un inhibidor del receptor del factor de crecimiento endotelial vascular

Country Status (23)

Country Link
US (2) US20080306058A1 (es)
EP (1) EP1945217B1 (es)
JP (1) JP2009507871A (es)
KR (1) KR20080058376A (es)
AR (1) AR056194A1 (es)
AT (1) ATE555790T1 (es)
AU (1) AU2006291526B2 (es)
BR (1) BRPI0615881A2 (es)
CA (1) CA2621399A1 (es)
EC (1) ECSP088259A (es)
GT (1) GT200600411A (es)
IL (1) IL189984A0 (es)
MA (1) MA29788B1 (es)
MY (1) MY145751A (es)
NO (1) NO20081807L (es)
NZ (1) NZ566474A (es)
PE (1) PE20070457A1 (es)
RU (1) RU2424804C2 (es)
SA (1) SA06270315B1 (es)
SG (1) SG165371A1 (es)
TN (1) TNSN08112A1 (es)
TW (1) TWI325321B (es)
WO (1) WO2007031265A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CN101687801B (zh) 2007-04-17 2012-10-03 诺瓦提斯公司 用作癌症治疗的萘甲酸酰胺的醚
WO2009026408A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
WO2012094451A1 (en) * 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Novel ureas for the treatment and prevention of cancer
EP2786752B1 (en) * 2011-12-01 2019-06-12 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
CN104334543B (zh) * 2013-04-09 2017-08-25 广州慧柏瑞生物医药科技有限公司 抗新生血管的化合物、其中间体及其用途
CN106414402A (zh) * 2013-11-01 2017-02-15 宇部兴产株式会社 丙烯酰(氧基或氨基)五氟硫烷基苯化合物、其药学可接受的盐及其前药
CN104860885B (zh) * 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
JP2023515630A (ja) * 2020-02-28 2023-04-13 上▲海▼▲潤▼石医▲薬▼科技有限公司 Ｃｓｆ－１ｒキナーゼ阻害剤の使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
EP1212318B1 (de) * 1999-08-27 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte indolinone als tyrosinkinase inhibitoren
ATE415396T1 (de) * 2000-09-20 2008-12-15 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
ATE399766T1 (de) * 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
BR0311172A (pt) * 2002-05-13 2005-04-26 Children S Hospital Los Angele Tratamento e prevenção de formação de cicatriz anormal em quelóides e outras lesões ou ferimentos internos ou cutâneos
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
EP1522540A4 (en) * 2002-08-30 2011-08-10 Eisai R&D Man Co Ltd AZAARENE DERIVATIVES
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
BRPI0414011A (pt) * 2003-08-29 2006-10-24 Pfizer naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
AU2005206571B8 (en) * 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa

Also Published As

Publication number Publication date
EP1945217A2 (en) 2008-07-23
AU2006291526B2 (en) 2010-07-29
NO20081807L (no) 2008-05-16
RU2424804C2 (ru) 2011-07-27
CA2621399A1 (en) 2007-03-22
MY145751A (en) 2012-03-30
SG165371A1 (en) 2010-10-28
TNSN08112A1 (en) 2009-07-14
AU2006291526A1 (en) 2007-03-22
WO2007031265A2 (en) 2007-03-22
IL189984A0 (en) 2008-11-03
TWI325321B (en) 2010-06-01
RU2008114048A (ru) 2009-10-20
ECSP088259A (es) 2008-04-28
NZ566474A (en) 2011-05-27
JP2009507871A (ja) 2009-02-26
US20120172386A1 (en) 2012-07-05
KR20080058376A (ko) 2008-06-25
SA06270315B1 (ar) 2010-12-21
TW200744600A (en) 2007-12-16
MA29788B1 (fr) 2008-09-01
US20080306058A1 (en) 2008-12-11
EP1945217B1 (en) 2012-05-02
ATE555790T1 (de) 2012-05-15
BRPI0615881A2 (pt) 2011-05-31
GT200600411A (es) 2007-05-21
WO2007031265A3 (en) 2007-07-12
AR056194A1 (es) 2007-09-26

Similar Documents

Publication Publication Date Title
PE20070457A1 (es) Composicion que comprende un inhibidor del receptor del factor de crecimiento endotelial vascular
PE20200743A1 (es) Composiciones y metodos para modular el crecimiento del cabello
PE20071321A1 (es) Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
NI200700107A (es) (bifenil) ácidos carboxílicos y sus derivados
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR082428A1 (es) Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados
CL2011000159A1 (es) Compuestos derivados de 1,3-oxazin-2-ona, inhibidores de 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.
DE69231252D1 (de) Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten
PE20060857A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
AR068075A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
CO6640247A2 (es) Compuesto[5.6]heterociclico o una sal farmacológicamente aceptable del mismo útil para la prevención de enfermedades asociadas con el metabolismo óseo
ECSP077187A (es) Método de reducción de la fitotoxicidad
AR069596A1 (es) Regulador del crecimiento de plantas
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
ECSP11011412A (es) Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso
BRPI0813044A2 (pt) "composto, composição fungicida e método para o controle do fungo fitopatogênico de culturas"
PE20130149A1 (es) Derivados de la cromenona con actividad anti-tumoral
AR081421A1 (es) Carboxamidas utiles como microbicidas y composiciones que comprenden dichos compuestos
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.
CR10509A (es) Derivados de cinamoil-piperazina y su utilizacion como antagonistas de par-1
UY32004A (es) Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica
UY30301A1 (es) Ácidos bifenilcarboxílicos substituidos y sus derivados
UY32632A (es) Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed